Cardiomedex is a specialty contract research organization dedicated to cardiovascular diseases. Our company concept is unique and based on the generation of preclinical and early clinical proof-of concept evidence to optimize drug development.
Our company provides a global and translational vision for the biopharmaceutical industry:
- Highly specialized expertise in: cardiovascular disorders, cardio-oncology, neurocardiology and dysautonomia
- Our clinicians and outstanding scientists create a permanent connection between experimental research and the clinic.
Cardiomedex offers :
- Lead optimization: cellular and molecular tools for compound screening and device testing with highly sensitive biosensors using BRET-based technology
- Full preclinical services: Proof of concept and safety experiments using customized in vivo, ex vivo and in vitro assays
- First in man trials for early clinical proof of concept studies
- Clinical trials (phases I to IV) in a dedicated and internationally recognized clinical center for investigation, specializing in the autonomic nervous system and cardiometabolic disorders
- Strategic consulting for the drug development process, launch onto the market, therapeutic switching and lifecycle extension of existing drugs.